Clinical Trial Update: Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants [Phase 3]

View source ↗

Summary

Wyeth (now Pfizer) completed a Phase 3 trial evaluating a 13-valent pneumococcal conjugate vaccine in infants, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal | Phase 3 | Status: COMPLETED | Results posted: 2012-08-15